Microcap Ledger Spero Therapeutics, Inc. $SPRO
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Cambridge, MA
- Fiscal year end
- December 31
- Shares outstanding
- 58,234,827 [10-Q 2026-08-12]
What the company doesAI summary of filing
Spero Therapeutics is a clinical-stage biopharmaceutical company that develops treatments for rare diseases and diseases with high unmet medical need. The company's primary focus is tebipenem HBr, an oral carbapenem antibiotic in development to treat complicated urinary tract infections in adults; in September 2022, Spero licensed tebipenem HBr exclusively to GlaxoSmithKline for development and commercialization outside certain Asian territories, receiving an upfront payment of $66 million and becoming eligible for up to $525 million in milestone payments plus tiered royalties on net sales. Spero has not generated revenue from product sales and remains pre-revenue, though it receives milestone payments from its GSK collaboration and previously received government funding. The company discontinued development of two earlier-stage programs, SPR206 and SPR720, in 2025 to focus resources on supporting GSK's FDA approval efforts for tebipenem HBr. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $258.0K | −$16.75M | $10.51M | $50.77M | [10-Q 2026-08-12] |
| FY ended Dec 2025 | $66.80M | $8.57M | −$12.62M | $40.27M | [10-K 2026-03-26] |
| FY ended Dec 2024 | $47.98M | −$68.57M | −$23.44M | $52.89M | [10-K 2026-03-26] |
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-06 | 54,518,165 | [10-Q 2024-11-14] |
| 2025-03-21 | 55,900,641 | [10-K 2025-03-27] |
| 2025-05-01 | 55,910,641 | [10-Q 2025-05-13] |
| 2025-08-05 | 56,275,225 | [10-Q 2025-08-12] |
| 2025-11-06 | 56,339,295 | [10-Q 2025-11-13] |
| 2026-03-20 | 57,891,493 | [10-K 2026-03-26] |
| 2026-05-01 | 57,901,493 | [10-Q 2026-05-13] |
| 2026-08-07 | 58,234,827 | [10-Q 2026-08-12] |
- Shelf registration
- S-3 filed 2026-08-28; declared effective 2026-09-10 [S-3 2026-08-28]
Listing status
Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-02-28. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-02-28 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-02-28] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-03 | Zack Debra | grant | 162,311 | — | [4 2026-08-06] |
| 2026-06-23 | Deshpande Milind | grant | 10,000 | — | [4 2026-06-25] |
| 2026-06-23 | Tregoning Kathleen | grant | 10,000 | — | [4 2026-06-25] |
| 2026-06-23 | Smith Cynthia | grant | 10,000 | — | [4 2026-06-25] |
| 2026-06-23 | Vink Patrick V.J.J. | grant | 10,000 | — | [4 2026-06-25] |
| 2026-06-23 | Thomas Frank E | grant | 10,000 | — | [4 2026-06-25] |
| 2026-06-23 | Jackson Scott Thomas | grant | 10,000 | — | [4 2026-06-25] |
| 2026-06-23 | Pottage John C Jr | grant | 10,000 | — | [4 2026-06-25] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-28 | 8-K | Material agreement entered; Other events |
| 2026-08-28 | S-3 | Registration statement |
| 2026-08-12 | 8-K | Results of operations |
| 2026-08-12 | 10-Q | Quarterly report |
| 2026-07-14 | 8-K | Material agreement entered; New financial obligation; Regulation FD disclosure |
| 2026-06-25 | 8-K | Director or officer change; Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-06-22 | 8-K | Regulation FD disclosure; Other events |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-04-27 | DEF 14A | Proxy statement |
| 2026-04-13 | PRE 14A | Proxy statement |
| 2026-03-26 | 8-K | Results of operations |
Alerts for $SPRO
Email me when Spero Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.